Fundraising FoxEisai Innovation, Inc.
Corporate VCCambridge · Seed–Series A · 4 people tracked
Find your way into Eisai Innovation, Inc.
Each arrow is one introduction. Sign up to fill in the first one.
Ask Chris Jones to introduce you to Rod Cotton
You →Chris · together at Orchard Software →Rod
Ask Jamie Chen to introduce you to Yoshiharu Mizui
You →Jamie · together at H3 Biomedicine →Yoshiharu
Ask Sam Okafor to introduce you to Ryutaro (Taro) Adachi
You →Sam · together at Constellation Technology Ventures →Ryutaro
Sign up to find every way you can get introduced to Eisai Innovation, Inc.
- Your email: who you already know at Eisai Innovation, Inc., and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Eisai Innovation, Inc. team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Investment thesis
Eisai Innovation seeks to identify and invest in innovative biotech and digital health companies that create synergies with Eisai's scientific capabilities and network. The investment strategy focuses on cutting-edge drug modalities, digital healthcare solutions, and emerging technologies in therapeutic areas with high unmet medical needs, particularly oncology and neurology. Through venture investment and M&A, the firm aims to accelerate Eisai's transformation into a top-10 global healthcare company while fostering innovation and translating emerging research into patient-centric solutions.
Source: firm website, verified Sep 20, 2026.
Team · 4 people
from the firm's website & curated
What they invest in
from 27 of 30 portfolio companiesBiotech ×21Healthtech ×19Deep Tech ×13Medical Devices ×11AI & Machine Learning ×9Digital Health ×8SaaS ×2Wellness & Fitness ×2
HQs:United States×11Japan×4Australia×1China×1European Union×1
Who they back
founder profiles across 16 portfolio companiesFounding team size:solo founder×82 founders×53 founders×14+ founders×2
Where their founders studiedfrom 14 founders with education data
University of California, Berkeley ×2
What their founders studiedfrom 14 founders with field-of-study data
Life Sciences ×6Chemistry ×5Mathematics & Statistics ×2Physics ×2
Investments · 30 tracked
founders shown can be your intro pathBy year:2025 · 22024 · 13 dated
Hyku Biosciences develops small molecule therapeutics with novel mechanisms of action designed to covalently bind non-cysteine amino acids and inactivate disease-driving proteins.
BiotechDeep TechMedical DevicesBurlington, US
KLEEM CHAUDHARY(Executive Officer, Director, Promoter)inKu-Lung (Ken) Hsu, PhD(Endowed Associate Professor of Chemistry)Kleem Chaudhary, PhD(President & CEO)
BoardJOHN GUSTOFSON(Director)LAURA BRASS(Director)inLAURA TADVALKAR(Director)in
Co-investorsDroia VenturesNovartis Venture FundRA Capital
Sift Biosciences develops T-cell immunotherapies for cancer and autoimmune diseases, using an AI-driven discovery platform combined with metagenomics and high-throughput cellular screening to identify microbially derived molecules that activate memory T cells.
AI & Machine LearningBiotechHealthtechSan Carlos, US
Yue Clare Lou(Co-Founder & CEO)in
BoardKevin Barrett(Director)inAltar Munis(Director)
Co-investorsSBI HoldingsFifty YearsFREEFLOWLifespan Vision Ventures
PRISM BioLab is a biotechnology company that develops PepMetics, a proprietary drug discovery platform of small molecules designed to mimic α-helix or β-turn peptides, aiming to target proteins previously considered "undruggable." The company maintains a screening library of over 20,000 compounds and partners with pharmaceutical firms on drug discovery programs.
AI & Machine LearningBiotechDeep TechTokyo, JP
Co-investorsDBJ CapitalNewton Biocapital
Altoida builds a multi-modal Digital NeuroMarker Platform that combines augmented reality, sensor fusion, and explainable AI in a 10-minute self-administered assessment to detect early signs of Mild Cognitive Impairment and Alzheimer's disease.
AI & Machine LearningDigital HealthMedical Devices
Co-investorsAlpana VenturesDaniel GutenbergHikma VenturesM VenturesPolytech Ecosystem VenturesVI Partners+3 more
Arteryex combines blockchain and AI technology to leverage underutilized health data for personalized healthcare management and medical services.
AI & Machine LearningDigital HealthHealthtechWellness & Fitness
李 東瀛 (Dongying Li)(代表取締役 (CEO))東 太輝 (Taiki Higashi)(取締役副社長 / 最高財務責任者 (CFO))里見 健太 (Kenta Satomi)(最高技術責任者 / エンジニア育成責任者 (CTO))小野澤 侑 (Yu Onozawa)(最高執行責任者 / データビジネス事業部長 (COO))
Beren is a public benefit corporation developing novel medicines in partnership with patients, caregivers, clinicians, and health systems.
BiotechHealthtech
Jason Camm(Founder, President & Chief Executive Officer)inAaron Ondrey(Chief Financial Officer)inAlex Gold(Chief Medical Officer)inJennifer Spinella(Chief Regulatory Officer & Head of Quality)inIrene von Hennigs(SVP, Global Medical Affairs)inBennett Smith(SVP, Commercial)in
Co-investorsAlpha Wave GlobalNarya CapitalOctave Ventures LlcUTokyo Innovation Platform Co. Ltd.
Bliss BioPharma is a biopharmaceutical company focused on the CMC development and commercialization of biologics, including therapeutic monoclonal antibodies, bispecific antibodies, ADCs, recombinant proteins, and vaccines.
BiotechHealthtech
Caraway Therapeutics was a preclinical biopharmaceutical company developing small-molecule therapies modulating lysosomal function to treat neurodegenerative and rare diseases.
BiotechHealthtech
Co-investorsDementia Discovery FundMcCarthy CapitalMRL Ventures FundSV Health InvestorsAbbVieBridge Investments+9 more
Casma is a biotech company developing technology that uses the autophagy pathway to degrade disease targets for therapeutic applications.
BiotechDeep TechHealthtechBoston, US
Andrea Ballabio(Founder)Beth Levine(Founder)Herbert Virgin(Founder)James Hurley(Founder)in
Co-investorsAstellas Venture Management LLCThird Rock VenturesOno Venture Investment, Inc.The Column Group
Cogstate provides digital cognitive assessments, electronic clinical outcome assessment (eCOA) support, and endpoint data quality services for biopharmaceutical companies, academic institutions, and clinicians.
BiotechDigital HealthHealthtechMedical DevicesMelbourne, AU
Brad O'Connor(Chief Executive Officer)inDr. Ventola(Chief Science Officer)
Co-investorsDolby Family Ventures
Darmiyan develops medical AI and brain imaging software for early detection and monitoring of neurodegenerative diseases, particularly Alzheimer's.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesSan Francisco, US
Padideh Kamali-Zare(Founder)inKaveh Vejdani(Founder/Chief Medical and Technology Officer)in
BoardShirai Takehiro(Director)
Co-investorsAAF Management Ltd.IT-Farm CorporationSoma CapitalY CombinatorArkitekt VenturesBaleen Capital+6 more
eGenesis uses gene editing and genome engineering to develop porcine donor animals for cross-species organ transplantation, addressing organ failure treatment and transplant supply constraints.
BiotechDeep TechMedical Devices
Mike Curtis, Ph.D.(President & Chief Executive Officer)
Co-investorsAlta PartnersAltium CapitalFresenius Medical Care VenturesKhosla VenturesLux Capital
Iambic develops AI technologies for drug discovery, using a high-throughput experimental platform to design small-molecule medicines and advance a pipeline of clinical candidates for cancers such as HER2-driven, breast, and ovarian tumors.
AI & Machine LearningBiotechDeep TechSan Diego, US
Tom Miller(Co-Founder & CEO)inFred Manby(Co-Founder & CTO)inThomas Miller(Founder)inChao Zhang(Executive Officer)inTabbert Teng(Executive Officer)Neil Josephson(Chief Medical Officer)in
Co-investorsAscenta CapitalAbingworthCatalio Capital ManagementAlumni VenturesCatalio Capital Management, LPCoatue Management+7 more
Neuroglee provides remote dementia and memory care through a care team of navigators, clinicians, social workers, and pharmacists who coordinate treatment, offer 24/7 support, and connect patients and caregivers with community resources.
Digital HealthHealthtechLongevity
Aniket Singh Rajput(Founder)in
Co-investorsOpenspace Ventures
Numab develops multispecific antibody-based therapeutics using its proprietary λ-Cap and MATCH discovery and engineering platforms, aiming to improve on first-generation antibody therapies in potency, stability, effect duration, and safety.
BiotechDeep Tech
David Urech(Founder)in
Co-investorsHBM Healthcare InvestmentsHBM PartnersBiotechnology Value FundBlackRockForbionNovo Holdings+1 more
Ophidion is an early-stage CNS biopharmaceutical company developing a non-invasive carrier technology that delivers gene-silencing agents and other therapeutics across the blood-brain barrier into the brain.
BiotechDeep TechHealthtechBethlehem, US
Julie Miwa(Director, Promoter)inYacoub Habib(Executive Officer, Director, Promoter)
BoardMichael Lark(Director)Scott Fishman(Director)Claudine Bruck(Director)
Co-investorsDelaware Crossing Investor GroupRobin Hood Ventures
Oura Ring is a wearable smart ring that collects and analyzes 50+ personal health metrics to provide insights on sleep, fitness, and wellness for individual users.
HardwareHealthtechWellness & FitnessSan Francisco, US
Ashley Colley(Founder)Virpi Tuomivaara(Founder)inTom Hale(CEO)in
Co-investors125 VenturesA-Rod CorpAble PartnersAlumni VenturesBasecamp FundBold Capital Partners+32 more
Periotherapia develops antibody-based therapeutics targeting pathological periostin in the stromal environment to treat refractory diseases including cancer, diabetic retinopathy, and heart disease.
BiotechDeep TechDigital HealthHealthtechMedical DevicesOsaka, JP
Yoshiaki Taniyama(Director and Founder)Eiji Tahara(Representative Director, President, CEO and COO)
Co-investorsChishima Real Estate — Startup Investment
ProTgen is a clinical-stage biotechnology company developing targeted Notch activators that generate progenitor T cells to restore thymic function and adaptive immune competence.
BiotechHealthtechToronto
Juan Carlos Zuniga-Pflucker(Executive Officer, Director)
BoardFei Shen(Director)Ferdinand Massari(Director)
Co-investorsFACIT (Fight Against Cancer Innovation Trust)
Ractigen Therapeutics develops proprietary RNA delivery platforms for oligonucleotide therapeutics, enabling treatment of previously unreachable tissues and organs in the CNS and beyond the liver.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesSuzhou, CN
Dr. Long-Cheng Li(CEO and Founder)Dr. Moorim Kang(Chief Technology Officer)
Co-investorsSDIC Venture Capital
SEED Therapeutics develops de novo molecular glue degraders for targeted protein degradation, using its RITE3 platform to match E3 ligases with disease-causing target proteins.
BiotechDeep TechHealthtechKing of Prussia, US
Lan Huang(Ph.D.)inAvram Hershko, M.D.(Co-Founder)Lan Huang, Ph.D.(Co-Founder, CEO and Chairman)Ning Zheng, Ph.D.(Co-Founder)Michele Pagano, M.D.(Co-Founder)
SOLA Biosciences is a preclinical-stage biopharmaceutical company developing gene therapies for neurodegenerative diseases like ALS, Huntington's Disease, and Alzheimer's Disease by targeting misfolded proteins.
BiotechDeep TechMedical DevicesBoston, US
Keizo Koya(Founder and CEO)inAkinori Hishiya(Founder and CSF)in
Co-investorsMC Healthcare VenturesUTEC
Tacit Therapeutics develops RNA-based gene therapy approaches by redirecting cellular splicing processes to repair mutated genes.
BiotechDeep TechHealthtechSan Francisco, US
Co-investorsLaurier Startup FundMitsui Global InvestmentKdT VenturesMichigan Capital Network
Unlearn develops AI-powered digital twins and data analytics tools to optimize clinical trial design and execution for pharmaceutical companies.
AI & Machine LearningBiotechDeep TechEnterprise SoftwareSan Francisco, US
Charles Fisher(Founder & CEO)inAaron Smith(Founder)in
Co-investors8VCAlumni VenturesBasecamp FundDCVC (Data Collective)Flucas VenturesInsight Partners+5 more
Aptar Digital Health is a division of Aptar Pharma that designs and manufactures drug delivery systems and digital health solutions for the pharmaceutical and healthcare industries.
Digital HealthHealthtechMedical DevicesSaaS
Co-investorsKaristaSanofi VenturesVesalius Biocapital Partners
Allm uses information and communication technology to address healthcare disparities and mismatches, aiming to provide equitable medical and welfare services to all people.
AI & Machine LearningDigital HealthHealthtechMedical DevicesSaaS
Co-investorsAsia Africa Investment & Consulting (AAIC)Fast Track Initiative
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
ExcalipointVivacta Bio
Exits · 1
1 acquisitionsCarawayacq. by Merck
Portfolio news
latest coverage across their companies
Oura · ouraring.com · Jul 15, 2026
Frequently asked questions
- How many investments has Eisai Innovation, Inc. made?
- Eisai Innovation, Inc. has 30 tracked investments, 1 of which have exited, including 3 dated in the last 24 months.
- What stage does Eisai Innovation, Inc. invest at?
- Eisai Innovation, Inc. invests at the Seed, Series A stages.
- What is Eisai Innovation, Inc.'s typical check size?
- Eisai Innovation, Inc. typically writes checks of $5M.
- What sectors does Eisai Innovation, Inc. focus on?
- Eisai Innovation, Inc. focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Eisai Innovation, Inc. located?
- Eisai Innovation, Inc. is headquartered in Cambridge, US.
- Who does Eisai Innovation, Inc. co-invest with?
- Eisai Innovation, Inc. most often shares deals with Alumni Ventures, Basecamp Fund, FREEFLOW, among 97 tracked co-investors.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.